Full-Time
Posted on 7/10/2025
RNA-based medicines development and delivery platform
$134k - $210k/yr
Cambridge, MA, USA
In Person
Orbital Therapeutics creates RNA-based medicines (not including siRNA) and builds a platform that combines RNA design, delivery methods, data science, and automation to develop a wide range of therapies. Its initial focus areas are vaccines, immunomodulation, and protein replacement. The company develops and commercializes RNA medicines, selling them to healthcare providers who administer treatment to patients. It differentiates itself through an integrated platform that merges RNA technology with delivery and automated data-driven workflows to accelerate discovery and development. Led by experts in genetic medicine, including Dr. Giuseppe Ciaramella, the team leverages deep experience in antivirals, immunology, and biotherapeutics to guide research. The goal is to improve global health by making RNA medicines accessible for diseases previously difficult to treat.
Company Size
11-50
Company Stage
Acquired
Total Funding
$1.8B
Headquarters
San Francisco, California
Founded
2022
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases Transaction further strengthens BMS’s industry-leading cell therapy portfolio, expanding CAR T-cell access to more patients in the future Bristol Myers Squibb (NYSE: BMY, “BMS”) and Orbital Therapeutics (“Orbital”) today announced a definitive agreement under which BMS will acquire Orbital, a privately held biotechnology company pioneering a new generation of RNA medicines that reprogram the immune system in vivo , enabling treatments that provide the precision, control, and flexibility needed to address the underlying biology and unique complexities of each disease. “ In vivo CAR T represents a novel treatment approach that could redefine how we treat autoimmune diseases,” said Robert Plenge, MD, PhD, executive vice president, Chief Research Officer, BMS. “This acquisition enhances our robust cell therapy
International law firm Covington & Burling LLP has advised multinational biopharmaceutical company Bristol Myers Squibb in its definitive agreement to acquire biotech company Orbital Therapeutics.
"Since inception, Orbital has made significant strides developing a differentiated RNA platform designed to enable a new generation of RNA medicines that reach more tissues, address more diseases, and benefit more patients.
Orbital Therapeutics, a biotechnology company pioneering a new generation of RNA medicines that reprogramme the immune system in vivo to treat disease at its source, have appointed Adam Raff, as Senior Vice President, Clinical Development.
Orbital is developing OTX-201 for B cell-driven autoimmune diseases, where the therapeutic goal is to deplete autoreactive B cells and reset the immune system.